Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion, Harvard Bioscience Ink Distribution Deal

NEW YORK (GenomeWeb) – Fluxion Biosciences announced today that it has signed a distribution agreement for its BioFlux and IonFlux cellular analysis platforms with Harvard Bioscience.

BioFlux enables automated, high-throughput studies of cell-cell interactions, while microfluidics-based IonFlux is designed for ion channel research and drug discovery. Under the terms of the deal, Harvard Bioscience will offer the platforms to its customers in North America. Additional terms were not disclosed.

"IonFlux is a perfect fit with our other electrophysiology products, and extends our capabilities to high-throughput automated analysis," John Battista, North American sales director for electrophysiology products at Harvard Bioscience, said in a statement. "Similarly, the BioFlux system is a natural extension of our well-established Warner Instruments flow cell portfolio, permitting higher-throughput, microfluidic processing of eukaryotic and bacterial assays under flow."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.